{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"FLT3 Absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"FLT3 Present"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"FLT3 No Data"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"KIT Absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"KIT Present"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"KIT No Data"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"FLT3 and KIT = These are fused genes found in participants with this type of leukemia.","groups":[{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2, Escalated/Dose level 3 of 100 mg/m\\^2, and Escalated/Dose level 4 of 120 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose"}],"paramType":"NUMBER","populationDescription":"All treated participants in stratum 4: Participants who received at least 1 dose of study therapy.","reportingStatus":"POSTED","timeFrame":"At baseline (within 3 weeks before initiation of study therapy)","title":"Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at Baseline","type":"SECONDARY","unitOfMeasure":"participants"}